748 related articles for article (PubMed ID: 23369096)
41. Interactions between artemisinin derivatives and P-glycoprotein.
Wang Y; Li Y; Shang D; Efferth T
Phytomedicine; 2019 Jul; 60():152998. PubMed ID: 31301971
[TBL] [Abstract][Full Text] [Related]
42. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
Gu J; Fang X; Hao J; Sha X
Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
[TBL] [Abstract][Full Text] [Related]
43. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy.
Bansal T; Jaggi M; Khar RK; Talegaonkar S
J Pharm Pharm Sci; 2009; 12(1):46-78. PubMed ID: 19470292
[TBL] [Abstract][Full Text] [Related]
44. Structural and functional aspects of P-glycoprotein and its inhibitors.
Mollazadeh S; Sahebkar A; Hadizadeh F; Behravan J; Arabzadeh S
Life Sci; 2018 Dec; 214():118-123. PubMed ID: 30449449
[TBL] [Abstract][Full Text] [Related]
45. Effect of endogenous multidrug resistance 1 and P-glycoprotein expression on anticancer drug resistance in colon cancer cell lines.
Washio I; Nakanishi T; Ishiguro N; Bister B; Tamai I
Biopharm Drug Dispos; 2019 Jan; 40(1):32-43. PubMed ID: 30556139
[TBL] [Abstract][Full Text] [Related]
46. Overcoming multidrug-resistance in vitro and in vivo using the novel P-glycoprotein inhibitor 1416.
Xu Y; Zhi F; Xu G; Tang X; Lu S; Wu J; Hu Y
Biosci Rep; 2012 Dec; 32(6):559-66. PubMed ID: 22757751
[TBL] [Abstract][Full Text] [Related]
47. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Lee TD; Lee OW; Brimacombe KR; Chen L; Guha R; Lusvarghi S; Tebase BG; Klumpp-Thomas C; Robey RW; Ambudkar SV; Shen M; Gottesman MM; Hall MD
Mol Pharmacol; 2019 Nov; 96(5):629-640. PubMed ID: 31515284
[TBL] [Abstract][Full Text] [Related]
48. A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance.
Zahra R; Furqan M; Ullah R; Mithani A; Saleem RSZ; Faisal A
PLoS One; 2020; 15(6):e0233993. PubMed ID: 32484843
[TBL] [Abstract][Full Text] [Related]
49. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.
Ludwig JA; Szakács G; Martin SE; Chu BF; Cardarelli C; Sauna ZE; Caplen NJ; Fales HM; Ambudkar SV; Weinstein JN; Gottesman MM
Cancer Res; 2006 May; 66(9):4808-15. PubMed ID: 16651436
[TBL] [Abstract][Full Text] [Related]
50. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells.
Nanayakkara AK; Follit CA; Chen G; Williams NS; Vogel PD; Wise JG
Sci Rep; 2018 Jan; 8(1):967. PubMed ID: 29343829
[TBL] [Abstract][Full Text] [Related]
51. Synthesis and Anticancer Cytotoxicity of Azaaurones Overcoming Multidrug Resistance.
Tóth S; Szepesi Á; Tran-Nguyen VK; Sarkadi B; Német K; Falson P; Di Pietro A; Szakács G; Boumendjel A
Molecules; 2020 Feb; 25(3):. PubMed ID: 32050702
[TBL] [Abstract][Full Text] [Related]
52. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
[TBL] [Abstract][Full Text] [Related]
53. Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy.
Saneja A; Dubey RD; Alam N; Khare V; Gupta PN
Curr Cancer Drug Targets; 2014; 14(5):419-33. PubMed ID: 24720364
[TBL] [Abstract][Full Text] [Related]
54. Marine Natural Products as Models to Circumvent Multidrug Resistance.
Long S; Sousa E; Kijjoa A; Pinto MM
Molecules; 2016 Jul; 21(7):. PubMed ID: 27399665
[TBL] [Abstract][Full Text] [Related]
55. Multidrug resistance: can new drugs help chemotherapy score against cancer?
Goldman B
J Natl Cancer Inst; 2003 Feb; 95(4):255-7. PubMed ID: 12591977
[No Abstract] [Full Text] [Related]
56. Emerging nanodelivery strategies of RNAi molecules for colon cancer therapy: preclinical developments.
Binkhathlan Z; Alshamsan A
Ther Deliv; 2012 Sep; 3(9):1117-30. PubMed ID: 23035595
[TBL] [Abstract][Full Text] [Related]
57. Rack1 mediates Src binding to drug transporter P-glycoprotein and modulates its activity through regulating Caveolin-1 phosphorylation in breast cancer cells.
Fan Y; Si W; Ji W; Wang Z; Gao Z; Tian R; Song W; Zhang H; Niu R; Zhang F
Cell Death Dis; 2019 May; 10(6):394. PubMed ID: 31113938
[TBL] [Abstract][Full Text] [Related]
58. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
[TBL] [Abstract][Full Text] [Related]
59. 3-benzazecine-based cyclic allene derivatives as highly potent P-glycoprotein inhibitors overcoming doxorubicin multidrug resistance.
Titov AA; Niso M; Candia M; Kobzev MS; Varlamov AV; Borisova TN; Voskressensky LG; Colabufo NA; Cellamare S; Pisani L; Altomare CD
Future Med Chem; 2019 Aug; 11(16):2095-2106. PubMed ID: 31538529
[No Abstract] [Full Text] [Related]
60. Dual inhibition of P-glycoprotein and midkine may increase therapeutic effects of anticancer drugs.
Aynacıoğlu AŞ; Bilir A; Kadomatsu K
Med Hypotheses; 2017 Sep; 107():26-28. PubMed ID: 28915956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
